Natera, Inc.NTRA

$231.41+4.97 (+2.19%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$33B

Large-cap

+5024%

2016 — today

10-Year Price

+1726%

2016 — today

52-Week Range

$133.66$254.40

Current $231.41· 81%

Natera develops molecular testing services globally. Its reproductive health portfolio includes Panorama (NIPT), Vistara (single-gene disorders), Horizon (carrier screening), Spectrum (IVF), Anora (miscarriage analysis), and paternity testing. Beyond reproductive health, it offers Signatera for ctDNA tumor monitoring and Prospera for organ transplant rejection. The Constellation platform provides cloud-based bioinformatics. Natera operates via direct sales and global partnerships, including BGI and Foundation Medicine.

Valuation in context

P/E ratio

-142.0

N/A

Not meaningful — company is unprofitable

P/B ratio

18.5

Above average

Pricier than usual over the last 10 years

FCF Yield

0.3%

Historically high

Historically high relative to the last 10 years

Free · No credit card needed

Get alerted when NTRA is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.